The global market for biomarkers is expected to grow to $12.8 billion by 2012, up from $5.6 billion today. That represents a compound average annual growth rate of 18 percent, according to BCC Research, the Wellesley, Mass-based research firm in a report 2007. This is expected to increase to over $12.8 billion by 2012, a compound average annual growth rate (CAGR) of 18%. The firm said pre-clinical studies of drug development and diagnostics research applications accounted for nearly half of the total in 2007. The firm said public-private partnerships and the U.S. FDA's Critical Path Initiative are fostering the adoption of molecular markers and the use of imaging biomarkers as potential surrogate end-points in clinical trials. The use of biomarkers in oncology therapeutics is likely to be one of the foremost priorities followed by cardiovascular and CNS applications in the next 3 to 7 years.


Revenue forecast for global biomarkers market by segments, through 2012 in millions

1 10